Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pemoline
Drug ID BADD_D01705
Description In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
Indications and Usage For treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Marketing Status approved; illicit; investigational; withdrawn
ATC Code N06BA05
DrugBank ID DB01230
KEGG ID D00744
MeSH ID D010389
PubChem ID 4723
TTD Drug ID Not Available
NDC Product Code 51552-1286
UNII 7GAQ2332NK
Synonyms Pemoline | Phenylisohydantoin | Phenoxazole | Tradon | Pemoline Compounds | Compounds, Pemoline | Pemoline Magnesium | Magnesium, Pemoline | Cylert | PemADD
Chemical Information
Molecular Formula C9H8N2O2
CAS Registry Number 2152-34-3
SMILES C1=CC=C(C=C1)C2C(=O)N=C(O2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain upper07.01.05.003--
Aplastic anaemia01.03.03.002---
Blood acid phosphatase increased13.04.02.008---
Death08.04.01.001--
Depression19.15.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dyskinesia17.01.02.006--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001---
Hepatitis09.01.07.004---
Insomnia17.15.03.002; 19.02.01.002--
Irritability08.01.03.011; 19.04.02.013--
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Nausea07.01.07.001--
Nystagmus06.05.02.006; 17.02.02.006--
Oculogyric crisis06.05.02.002; 17.01.03.002---
Oculomotor study abnormal13.07.04.012---
Prostatic disorder21.04.01.001---
Rash23.03.13.001---
Seizure17.12.03.001--
Somnolence17.02.04.006; 19.02.05.003--
Tongue movement disturbance07.14.02.016; 17.02.05.049---
Tourette's disorder03.10.01.001; 17.19.02.001; 19.11.04.002---
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Growth retardation05.03.02.007; 14.03.02.031; 15.03.05.016--
Hepatic enzyme increased13.03.04.028---
Decreased appetite08.01.09.028; 14.03.01.005--
The 1th Page    1    Total 1 Pages